Biguanides and dipeptidyl peptidase-4 inhibitors use have similar outcomes for diabetic patients
1. Biguanides and dipeptidyl peptidase-4 (DPP-4) inhibitors show no differences in major cardiac or cerebrovascular events, diabetic complications, or death in the Japanese population. Evidence Rating Level: 2 (Good) The initial pharmacologic intervention for type...